<SEC-DOCUMENT>0001178913-26-001161.txt : 20260318
<SEC-HEADER>0001178913-26-001161.hdr.sgml : 20260318
<ACCEPTANCE-DATETIME>20260318093518
ACCESSION NUMBER:		0001178913-26-001161
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260318
FILED AS OF DATE:		20260318
DATE AS OF CHANGE:		20260318

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Raviv Adi
		CENTRAL INDEX KEY:			0001098565
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37353
		FILM NUMBER:		26766262

	MAIL ADDRESS:	
		STREET 1:		STRAUS CAPITAL GROUP
		STREET 2:		411 HACKENSACK AVENUE, 7TH FLOOR
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER NAME:	
		FORMER CONFORMED NAME:	RAVIV ADI
		DATE OF NAME CHANGE:	19991108

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scinai Immunotherapeutics Ltd.
		CENTRAL INDEX KEY:			0001611747
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		JERUSALEM BIOPARK, 2ND FLOOR
		STREET 2:		HADASSAH EIN KEREM CAMPUS
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			00000
		BUSINESS PHONE:		972-8-9302529

	MAIL ADDRESS:	
		STREET 1:		JERUSALEM BIOPARK, 2ND FLOOR
		STREET 2:		HADASSAH EIN KEREM CAMPUS
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BiondVax Pharmaceuticals Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>zk2634727.xml
<DESCRIPTION>FORM 3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0607</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2026-03-18</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001611747</issuerCik>
        <issuerName>Scinai Immunotherapeutics Ltd.</issuerName>
        <issuerTradingSymbol>SCNI</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001098565</rptOwnerCik>
            <rptOwnerName>Raviv Adi</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SCINAI IMMUNOTHERAPEUTICS LTD.</rptOwnerStreet1>
            <rptOwnerStreet2>JERUSALEM BIOPARK, 2ND FLOOR</rptOwnerStreet2>
            <rptOwnerCity>JERUSALEM</rptOwnerCity>
            <rptOwnerState></rptOwnerState>
            <rptOwnerZipCode>9112002</rptOwnerZipCode>
            <rptOwnerStateDescription>ISRAEL</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>American Depositary Shares</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary shares, no par value per share (&quot;Ordinary Shares&quot;)</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>200000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.005</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-08-24</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1720000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.005</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-08-24</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>8000000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.0004</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F5"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-12-22</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>48200000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Represents 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares, at the holder's election and have no expiration date.</footnote>
        <footnote id="F2">The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.</footnote>
        <footnote id="F3">The option vests in one installment on August 24, 2027, subject to the Reporting Person's continued service through such date.</footnote>
        <footnote id="F4">The option vests in three equal annual installments commencing August 24, 2024, subject to the Reporting Person's continued service through such dates.</footnote>
        <footnote id="F5">The option vests in three equal annual installments commencing December 22, 2026, subject to the Reporting Person's continued service through such dates.</footnote>
    </footnotes>

    <remarks>Exhibit 24 - Power of Attorney.</remarks>

    <ownerSignature>
        <signatureName>/s/ Amir Reichman, Attorney-in-Fact</signatureName>
        <signatureDate>2026-03-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>exhibit_24.htm
<DESCRIPTION>EXHIBIT 24
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: zk-global
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 24</font></u><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">LIMITED POWER OF ATTORNEY<br>
      </font><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Know all by these present, that the undersigned hereby constitutes and appoints each of Amir Reichman and Uri Ben-Or
      (each, an &#8220;<font style="font-weight: bold; font-style: italic;">Attorney-in-fact</font>&#8221;), or any of them acting singly and with full power of substitution, as the undersigned&#8217;s true and
      lawful attorney-in-fact to:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: -14.2pt; margin-left: 49.65pt; line-height: 1.25;">1. prepare, submit, execute for, and on behalf of the undersigned, in the undersigned&#8217;s
      capacity as an officer or director, as applicable, of Scinai Immunotherapeutics Ltd. (the &#8220;Company&#8221;), (a) Forms 3, 4, and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the
      rules promulgated thereunder and (b) any other forms or reports the undersigned may be required to file in connection with the undersigned&#8217;s ownership, acquisition, or disposition of securities of the Company with the Securities and Exchange
      Commission (the &#8220;SEC&#8221;) on the Electronic Data Gathering, Analysis, and Retrieval system (&#8220;EDGAR&#8221;) of the SEC;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: -14.2pt; margin-left: 49.65pt; line-height: 1.25;">2. do and perform any and all acts for and on behalf of the undersigned which may be
      necessary or desirable to complete and execute any such Form 3, 4, or 5, or other form or report (or any amendment thereto), and timely file such schedule, form or report with the SEC on EDGAR and any stock exchange or similar authority;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: -14.2pt; margin-left: 49.65pt; line-height: 1.25;">3. seek or obtain, as the undersigned&#8217;s representative and on the undersigned&#8217;s behalf,
      information on transactions in the Company&#8217;s securities from any broker or financial institution, and the undersigned hereby authorizes any such person to release any such information to each of the Attorneys- in-fact and approves and ratifies any
      such release of information; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: -14.2pt; margin-left: 49.65pt; line-height: 1.25;">4.&#160; take any other action of any type whatsoever in connection with the foregoing which, in
      the opinion of such Attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such Attorney-in-fact on behalf of the undersigned pursuant to this Power
      of Attorney shall be in such form and shall contain such terms and conditions as such Attorney-in-fact may approve in such Attorney-in-fact&#8217;s discretion.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The undersigned acknowledges that this Power of Attorney authorizes, but does not require, the Attorney-in-Fact to
      act in his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information, and any documents prepared or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of
      Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary or desirable.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The undersigned hereby grants to each such Attorney-in-Fact full power and authority to do and perform any and every
      act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of
      substitution or revocation, hereby ratifying and confirming all that such Attorneys-in-Fact, or such Attorney-in-Fact's designated substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and
      powers herein granted. The undersigned acknowledges that the foregoing Attorneys-in-Fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is Scinai Immunotherapeutics Ltd. assuming, any of the undersigned&#8217;s
      responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, and this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned&#8217;s obligations under Section 13 or Section 16 of the
      Exchange Act, including, without limitation, the reporting requirements under Section 13 or Section 16 of the Exchange Act.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Power of Attorney, with respect to
        each of the Attorneys-in-Fact, shall remain in full force and effect until the earlier of (a) the date that the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned&#8217;s beneficial ownership and transactions in
        securities issued by the Company, (b) this Power of Attorney is revoked by the undersigned in a signed writing delivered to such Attorneys-in-Fact, or (c) the time at which such Attorney-in-Facts are no longer employed by Scinai
      Immunotherapeutics Ltd.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of this 18<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day of March, 2026.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin: 0px 0px 0px 50%; line-height: 1.25;">SIGNED AND ACKNOWLEDGED</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin: 0px 0px 0px 50%; line-height: 1.25;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By: <u>/s/ Adi Raviv</u></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Name: Adi Raviv</div>
    </div>
    <div style="margin: 0px 0px 0px 50%; line-height: 1.25;"> <br>
    </div>
  </div>
  <div>
    <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
